Concord Biotech Gets USFDA Nod for Mycophenolate Mofetil ANDA

Concord Biotech Ltd has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This immunosuppressant is used for organ transplant recipients. The U.S. market for this drug is estimated at $30 million. This approval is expected to enhance Concord Biotech's product offerings, strengthen its market position in the U.S., and support its long-term growth strategy.